Skip to main content

Table 1 Patient demographic and clinical characteristics.

From: The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: A preliminary trial

  Q+CBT
(N = 11)
P+CBT
(N = 11)
All patients
(N = 31)
Women 8 (73%) 8 (73%) 23 (74%)
Average age 41.6 ± 13 44.9 ± 10 43.7 ± 11
Average # of treatments*f 3 ± 1 3 ± 1 3 ± 1
Average onset of depression 21 ± 15 mo 24 ± 15 mo 22.7 ± 16 mo
Prior augmentation ** 4 (36%) 4 (36%) 11 (35%)
Prior ECT*** 1 1 2
Mean HADS at screen 30 ± 6.4 29.8 ± 6.7 28.4 ± 6.7
Mean HRSD at screen 23.4 ± 3 22.4 ± 4.7 23 ± 3.5
Mean MADRS at screen 30.5 ± 3 29.8 ± 5 30.7 ± 4
Mean CGI at screen 4.2 ± 0.4 4.2 ± 0.4 4.2 ± 0.4
  1. * Although patients had, on average, 3 adequate antidepressant trials (see f) many also received antidepressants at lower dosages than those described below.
  2. fTherapeutically recommended daily doses were; venlafaxine, 225 mg/350 mg (moderate, severe depression, respectively), citalopram 40 mg, sertraline 200 mg, mirtazapine 45 mg, nefazodone 600 mg, paroxetine 50 mg, amitriptyline 300 mg, phenelzine 90 mg [17, 18].
  3. ** With either lithium carbonate or an atypical antipsychotic.
  4. *** Electroconvulsive therapy.